Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)
暂无分享,去创建一个
C. Denkert | H. Ulmer | R. Wirtz | G. von Minckwitz | S. Darb-Esfahani | A. Noske | S. Loibl | B. Müller | M. Roller | R. Kronenwett | G. Minckwitz | J. Steffen | C. Toerne | I. Baumann | G. Hoffmann | G. Heinrich | S. Graßhoff | S. Grasshoff | bullet S Loibl | bullet S Darb-Esfahani | bullet M Roller | bullet R Kronenwett | bullet B M Mü | bullet J Steffen | bullet C Von Toerne | bullet R Wirtz | bullet I Baumann | bullet G Hoffmann | bullet G Heinrich | bullet S T Grasshoff | bullet H U Ulmer | bullet C Denkert | bullet G Von Minckwitz | Á. S. Darb-Esfahani | Á. B. M. Müller | Á. C. Denkert | Á. M. Roller | Á. J. Steffen | Á. G. Von Minckwitz | Á. C. Von Toerne | Á. R. Wirtz
[1] C. Denkert,et al. Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.
[2] M. Untch,et al. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] R. Aft,et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. , 2009, American journal of surgery.
[4] W. Weichert,et al. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy , 2009, Breast Cancer Research.
[5] Uwe Rogel,et al. RNA extraction from archival formalin-fixed paraffin-embedded tissue: a comparison of manual, semiautomated, and fully automated purification methods. , 2009, Clinical chemistry.
[6] C. Denkert,et al. Neoadjuvant chemotherapy in operable breast cancer with docetaxel, doxorubicin, and cyclophosphamide (TAC) or TAC followed by vinorelbine and capecitabine (NX): Final results and analysis of markers predicting response to treatment. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Kristiansen,et al. Quantitative determination of predictive cancer biomarkers in formalin-fixed, paraffin-embedded tissue using a new, fully automated method for RNA isolation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Tutt,et al. A single-tube quantitative assay for mRNA levels of hormonal and growth factor receptors in breast cancer specimens. , 2009, The Journal of molecular diagnostics : JMD.
[9] Robin L. Jones,et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer , 2009, Breast Cancer Research and Treatment.
[10] M. Dimopoulos,et al. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: A Hellenic Cooperative Oncology Group (HeCOG) study , 2008, British Journal of Cancer.
[11] A. Gown. Current issues in ER and HER2 testing by IHC in breast cancer , 2008, Modern Pathology.
[12] S. Loibl,et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.
[13] S. Loibl,et al. Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.
[14] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Chaudhuri,et al. HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .
[17] G. Hortobagyi,et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.
[18] A. Schneeweiss,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] T. Karn,et al. The erbB2+ cluster of the intrinsic gene set predicts tumor response of breast cancer patients receiving neoadjuvant chemotherapy with docetaxel, doxorubicin and cyclophosphamide within the GEPARTRIO trial. , 2007, Breast.
[20] C. Perou,et al. The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.
[21] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[22] Robin L. Jones,et al. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer , 2007, Breast Cancer Research and Treatment.
[23] D. Hayes,et al. New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK , 2006, Breast Cancer Research and Treatment.
[24] Andreas Makris,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Berry. Chemotherapy is More Effective in Patients With Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment , 2006 .
[27] Berthold Streubel,et al. Expression of HER2 and the Coamplified Genes GRB7 and MLN64 in Human Breast Cancer: Quantitative Real-time Reverse Transcription-PCR as a Diagnostic Alternative to Immunohistochemistry and Fluorescence In situ Hybridization , 2005, Clinical Cancer Research.
[28] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[29] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[30] A. Luini,et al. Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors , 2004, Clinical Cancer Research.
[31] D. Birnbaum,et al. Comparative multi‐methodological measurement of ERBB2 status in breast cancer , 2004, The Journal of pathology.
[32] A. Gown,et al. Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? , 2004, Human pathology.
[33] Jinha M. Park,et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] John J Spinelli,et al. HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.
[35] M. Untch,et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.